Secured $96M Series C Financing; Total Raised Since 2019 Founding Exceeds $450M Proceeds Fund the Clinical Development of TORL-1-23, Currently in a Registrational Phase 2 Study for Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer and in Phase 1 for other CLDN6+ Cancers...
Hence then, the article about torl biotherapeutics secures 96m series c financing and presents updated phase 1 results of novel claudin 6 targeted antibody drug conjugate torl 1 23 at the 2025 european society of medical oncology congress was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2025 European Society of Medical Oncology Congress )
Also on site :
- Ann Godoff, Penguin Press Founder and Editor, Dies at 76
- WI vs SA Dream11 Prediction Today Match, Dream11 Team Today, Fantasy Cricket Tips, Playing XI, Pitch Report, Injury Update- ICC T20 World Cup 2026, Match 47
- Megan Thee Stallion Has One Question for Juvenile About Their Rumored ‘B.B.B.’ Remix: ‘When You Gonna Drop It?’